{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:39:39Z","timestamp":1787243979656,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clml.2017.07.007","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T22:32:04Z","timestamp":1500589924000},"page":"852-856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review"],"prefix":"10.1016","volume":"17","author":[{"given":"Anthony R.","family":"Mato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan C.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.07.007_bib1","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.07.007_bib2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.07.007_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.07.007_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.07.007_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.07.007_bib6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","article-title":"Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"22","author":"Kharfan-Dabaja","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.07.007_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bmt.1705619","article-title":"Graft-versus-leukemia in chronic lymphocytic leukemia","volume":"39","author":"Ben-Bassat","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.07.007_bib8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2015-03-585091","article-title":"A\u00a0drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs","volume":"126","author":"Mato","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib9","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2017.07.007_bib10","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.V124.21.1982.1982","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL","volume":"124","author":"Porter","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib11","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.07.007_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/152581602753658448","article-title":"Nonmyeloablative allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Baron","year":"2002","journal-title":"J\u00a0Hematother Stem Cell Res"},{"key":"10.1016\/j.clml.2017.07.007_bib13","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2684::AID-CNCR13>3.0.CO;2-V","article-title":"The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia","volume":"86","author":"Diehl","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.07.007_bib14","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.07.007_bib15","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.07.007_bib17","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.07.007_bib18","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib19","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/mt.2011.167","article-title":"Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma","volume":"19","author":"Gerdemann","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.clml.2017.07.007_bib20","doi-asserted-by":"crossref","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med J"},{"key":"10.1016\/j.clml.2017.07.007_bib21","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1182\/blood-2011-09-378398","article-title":"Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation","volume":"119","author":"Hardy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib22","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1182\/blood.V122.21.2874.2874","article-title":"Adoptive immunotherapy with autologous CD3\/CD28-costimulated T-cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia","volume":"122","author":"Schuster","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib23","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.07.007_bib25","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.07.007_bib26","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V128.22.56.56","article-title":"CD19 CAR-T cells are highly effective in ibrutinib-refractory chronic lymphocytic leukemia","volume":"128","author":"Turtle","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib28","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T\u00a0cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2017.07.007_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.07.007_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","article-title":"Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.07.007_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood.V126.23.264.264","article-title":"4SCAR19 chimeric antigen receptor-modified T cells as a breakthrough therapy for highly chemotherapy-resistant late-stage B cell lymphoma patients with bulky tumor mass","volume":"126","author":"Chang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib33","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1182\/blood-2016-01-692046","article-title":"Chimeric antigen receptor T cells targeting Fc \u03bc receptor selectively eliminate CLL cells while sparing healthy B cells","volume":"128","author":"Faitschuk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib34","doi-asserted-by":"crossref","first-page":"e0128151","DOI":"10.1371\/journal.pone.0128151","article-title":"Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations","volume":"10","author":"Deniger","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2017.07.007_bib35","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.07.007_bib36","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1073\/pnas.1524193113","article-title":"Versatile strategy for controlling the specificity and activity of engineered T cells","volume":"113","author":"Ma","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2017.07.007_bib37","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2017.07.007_bib38","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/blood.V124.21.1186.1186","article-title":"Ibrutinib treatment of relapsed CLL following allogeneic transplantation: sustained disease response and promising donor immune modulation","volume":"124","author":"Ryan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib39","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib40","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.07.007_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1309\/AJCP59UORCYZEVQO","article-title":"Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma","volume":"137","author":"Alapat","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2017.07.007_bib42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.V128.22.58.58","article-title":"Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed\/refractory CLL","volume":"128","author":"Geyer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7509","article-title":"CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL","volume":"35","author":"Gill","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.07.007_bib44","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.007_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.103","article-title":"The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL)","volume":"35","author":"Maude","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.07.007_bib46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.998.998","article-title":"LBA-6 Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1","volume":"128","author":"Neelapu","year":"2016","journal-title":"Blood"},{"issue":"suppl S2","key":"10.1016\/j.clml.2017.07.007_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) \u2014 an interim analysis","volume":"35","author":"Schuster","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2017.07.007_bib48","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:14Z","timestamp":1761870674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017309564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S2152265017309564"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.07.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}